Ibrahim Aldoss, MD

home / authors / ibrahim-aldoss-md

Associate professor, Division of Leukemia, Department of Hematology & Hematopoietic Cell Transplantation, City of Hope.

Articles

July 1st 2025

Early SYRUS Data Highlight Safety, Efficacy of AZD0486 in Relapsed/Refractory B-Cell ALL: Ibrahim Aldoss, MD

AZD0486 demonstrated encouraging safety and dose-dependent efficacy in heavily pretreated adolescent and adult patients with relapsed/refractory B-cell acute lymphoblastic leukemia (ALL), according to early findings from the phase 1/2 SYRUS trial and Ibrahim Aldoss, MD, of City of Hope.

June 28th 2025

SYRUS Study Explores AZD0486 Safety, Dosing in Relapsed/Refractory B-Cell ALL: Ibrahim Aldoss, MD

Brooke McCormick Ibrahim Aldoss, MD

Ibrahim Aldoss, MD, discusses the potential of AZD0486 for treating relapsed or refractory B-cell acute lymphoblastic leukemia (ALL) and outlines the SYRUS study objectives.

Ibrahim Aldoss, MD, associate professor, City of Hope

June 1st 2025

Ponatinib in Ph+ ALL and MRD Negativity: Ibrahim Aldoss, MD

Pearl Steinzor Ibrahim Aldoss, MD

Ibrahim Aldoss, MD, associate professor, City of Hope, explores recent findings on ponatinib as a first-line treatment for Philadelphia chromosome–positive acute lymphoblastic leukemia (Ph+ ALL).